Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2020 | HER2CLIMB: tucatinib in combination w/ capecitabine & trastuzumab

Giuseppe Curigliano • 14 May 2020
ESMO Breast 2020
Breast Cancer Antibodies Capecitabine Trastuzumab Tucatinib

Giuseppe Curigliano, MD, PhD, University of Milano, Milan, Italy, discusses the HER2CLIMB trial (NCT02614794) which investigated tucatinib vs. placebo in combination with capecitabine and trastuzumab in patients with advanced HER2+ breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Giuseppe Curigliano

6:54
Key clinical trials investigating immunotherapy in HER2+ and HR+ breast cancer
Giuseppe Curigliano • 9 Dec 2021
2:49
PROCURE: Genomic signatures and adjuvant chemotherapy for breast cancer in Europe
Giuseppe Curigliano • 9 Dec 2021
2:52
Future research directions for breast cancer
Giuseppe Curigliano • 9 Dec 2021
1:51
Reflecting on the use of CDK4/6 inhibitors in HR+ breast cancer
Giuseppe Curigliano • 25 Mar 2021

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals